Engitix Therapeutics
Generated by Meeveem AI
"Unlocking ECM-based therapies for fibrosis and cancer"
About Engitix Therapeutics
Engitix Therapeutics is a London biotechnology company developing treatments for fibrosis, inflammation and solid tumours by studying the extracellular matrix (ECM), the structural and signalling environment around cells. Its discovery platform combines a large human ECM bioarchive, 3D human cell models and artificial intelligence to identify drug targets and explore how potential treatments affect diseased tissue.
Founded in 2016 from University College London research, Engitix develops both internal and partnered therapeutic programmes. Its team works from purpose-designed offices and laboratories at White City Place. Collaborations with GSK, Lonza, Takeda and Dompé connect its ECM research with drug discovery and development.
Research environment
The White City facility brings purpose-designed office and laboratory space together across 13,000 square feet. Engitix also has a staff Shadow Board that provides feedback to leadership, giving employees a route to contribute to how the organisation develops.
58
Team Members
2016
Founded
Biotechnology
Sector
On-Site
Work Environment